This study will look into testing a new medicine called NNC0363-1063 which may be used to treat people with diabetes. The study consists of three parts: Part 1 is a single ascending dose (SAD) study that comprises two subtypes: Part 1A conducted in healthy participants and Part 1B conducted in participants with type 1 diabetes (T1D). This study part will last for about 1½ to 5½ weeks. Part 2 is a proof-of-principle (PoP) study part conducted in participants with T1D and will last for about 3½ to 8½ weeks. Part 3 is a meal test multiple dose study part conducted in participants with T1D and will last for 7 to 11 weeks.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part 1 SAD: Number of adverse events
Timeframe: From investigational medicinal product (IMP) administration (day 1) until end of study visit (day 8)
Part 2 PoP: CL/F,I1063,SD- Apparent serum clearance of NNC0363-1063 after a single dose
Timeframe: From IMP administration at day 1 up to 7 days
Part 3 Meal test: AUC,PG,meal: Area under the plasma glucose concentration-time curve at steady state
Timeframe: At day 2 of visit 2 and visit 3 after initiation of meal test